-
The incidence of serious adverse events was numerically higher with febuxostat than with placebo, but the difference between treatments was not statistically significant.
非布索坦组严重不良反应在数量上多于安慰剂组,但是没有统计学上的显著性差异。
-
Results The key intermediate 4 for the synthesis of febuxostat was synthesized via a four-step procedure in a total yield of 22.6% and its structure was confirmed by 1H-NMR and ESI-MS.
结果 经四步反应合成非布司他关键中间体4,总收率为22.6%,其结构经核磁共振氢谱、质谱确证。
1. Febuxostat 翻译:非布索坦\nFebuxostat是一种新的非嘌呤类黄嘌呤氧化酶抑制剂,临床上用于治疗尿酸过高症(痛风),疗效不亚于别嘌呤醇,且较少出现过敏。